Vulval Lesion Excision — Cost, Top Hospitals & Success Rates | MyMedicPlus

Vulval lesion excision is a surgical procedure performed to remove abnormal tissue from the vulva — the external female genitalia, comprising the labia majora, labia minora, clitoris, vestibule, and perineum. The procedure ranges in extent from a simple local excision of a small benign cyst or wart under local anesthesia to a wide local excision with clear tissue margins for premalignant or early malignant conditions, and in some cases a more extensive radical excision for confirmed vulval cancer.

Vulval lesions are encountered in women of all ages. Benign lesions such as Bartholin gland cysts, sebaceous cysts, fibromas, condylomata acuminata (genital warts), and epidermal inclusion cysts are common and rarely require excision unless symptomatic or enlarging. Premalignant conditions — most importantly vulval intraepithelial neoplasia (VIN) — have increased in incidence over the past two decades, particularly in women under 50, driven by human papillomavirus (HPV) infection. VIN carries a risk of progression to invasive vulval squamous cell carcinoma (SCC) if untreated.

Vulval carcinoma (most commonly SCC) is the fourth most common gynaecological cancer, accounting for approximately 4% of female genital malignancies. Surgical excision remains the cornerstone of treatment. The surgical approach has evolved significantly over the past 30 years, away from radical en-bloc vulvectomy toward individualized, defect-minimizing procedures that optimize oncological safety while preserving anatomical form, sexual function, urinary continence, and psychological well-being.

All excised tissue is submitted for formal histopathological examination, which confirms the diagnosis, assesses surgical margins, and determines whether further treatment (re-excision, radiation, systemic therapy) is required. This guide provides comprehensive information on vulval lesion excision to help patients make informed decisions about their care.

Vulval lesion excision is indicated for a wide spectrum of conditions spanning benign, premalignant, and malignant pathology:

Benign Conditions

• Bartholin gland cysts and abscesses: The Bartholin glands (located at the posterior introitus) can become obstructed, forming cysts or infected abscesses. Marsupialisation (creating a permanent opening) or excision of the gland is performed for recurrent cysts or abscesses that do not respond to incision and drainage, especially in postmenopausal women (to exclude malignancy).
• Sebaceous and epidermal inclusion cysts: Small, superficial cysts arising from obstructed skin glands. Excision is straightforward under local anesthesia.
• Condylomata acuminata (genital warts): Caused by low-risk HPV (types 6, 11). Extensive, symptomatic, or treatment-resistant warts may be excised surgically or with laser/electrosurgery.
• Fibromas and lipomas: Benign soft tissue tumours that may grow large and cause discomfort, requiring excision.
• Hidradenitis suppurativa: Chronic inflammatory disease of the apocrine glands causing painful nodules, abscesses, and sinus tracts in the vulva and perineum. Wide excision of affected skin is used for refractory cases.
• Vulval varicosities: Varicose veins of the vulva causing discomfort, occasionally treated by excision.

Premalignant Conditions

• Vulval intraepithelial neoplasia (VIN): Previously classified as VIN 1/2/3, now reclassified by WHO into usual-type VIN (uVIN) — HPV-related, more common in younger women — and differentiated VIN (dVIN) — HPV-independent, associated with lichen sclerosus, more common in older women, with a significantly higher (up to 33%) risk of progression to invasive cancer. Wide local excision with a minimum 5 mm clear margin is standard treatment for VIN.
• Paget's disease of the vulva: A rare intraepithelial adenocarcinoma presenting as a red, eczematous, pruritic plaque. Wide excision is the mainstay but achieving clear margins is challenging due to the extent of subclinical disease.

Malignant Conditions

• Squamous cell carcinoma (SCC) of the vulva: Accounts for ~90% of vulval cancers. Wide local excision or radical excision with or without sentinel lymph node biopsy/inguinofemoral lymphadenectomy is the primary treatment for early-stage disease.
• Vulval melanoma, Bartholin gland carcinoma, and other rare malignancies: Treated with excision tailored to tumour type and stage.

Any woman with a vulval lesion requiring diagnosis, treatment, or both may be a candidate for excision. The assessment process determines the appropriate surgical approach:

Pre-operative Assessment

• Clinical examination and colposcopy: A detailed examination of the vulva, vagina, and cervix under magnification (colposcopy) maps the extent and characteristics of the lesion. Acetic acid application and toluidine blue dye may help delineate margins for biopsy guidance.
• Punch or incisional biopsy: Before proceeding to formal excision, representative tissue sampling from suspicious areas is performed (usually under local anesthesia in the outpatient setting) to obtain histological diagnosis and confirm the grade of VIN or presence of invasive cancer. This avoids overtreatment and guides the required surgical margins.
• Imaging for invasive cancer: MRI of the pelvis is used to assess tumour size, depth of invasion, and pelvic lymph node status. CT chest-abdomen-pelvis or PET-CT may be needed for staging in confirmed malignancy.
• Cervical cytology and HPV testing: As the vulva and cervix share HPV-related oncogenic pathways, a contemporaneous cervical smear and HPV test are important components of the evaluation.

Who Is Eligible

• Women with histologically confirmed VIN (usual or differentiated type)
• Women with Paget's disease of the vulva
• Women with early invasive vulval SCC (FIGO Stage IA/IB/II) suitable for surgical management
• Women with symptomatic, enlarging, or recurrent benign lesions
• Postmenopausal women with new vulval lesions (warrant biopsy/excision to exclude dVIN or malignancy)

Patients with serious medical comorbidities who are high surgical risk may be assessed for non-surgical alternatives (see Alternatives section). There is no strict upper age limit for vulval surgery; decisions are based on fitness for anesthesia rather than age per se.

The surgical approach is tailored to the nature, site, and extent of the lesion:

1. Local Excision

Used for small, clearly defined benign lesions (cysts, fibromas, small condylomata). Performed under local anesthesia in an outpatient or day-surgery setting. The lesion is excised with a small rim of surrounding normal tissue. The wound is closed with absorbable sutures. Recovery is rapid (5–10 days).

2. Wide Local Excision (WLE)

The standard treatment for VIN and early invasive vulval cancer (lesion <2 cm, invasion <1 mm for Stage IA). A margin of at least 5–10 mm of histologically normal tissue is excised around the lesion. The specimen is oriented and sent for histopathological assessment of margins. If margins are involved, re-excision is typically required within 4–6 weeks. WLE can usually be performed under general or regional (spinal) anesthesia as a day-case or with one-night hospital stay. Skin closure is achieved primarily in most cases; occasionally a small V-Y advancement flap or Z-plasty is used to close larger defects without tension.

3. Radical Local Excision

For confirmed invasive vulval carcinoma (Stage IB and above), a wider excision with at least a 1–2 cm clinical margin is performed. The depth of excision includes the dermis and underlying subcutaneous tissue down to the fascia. For lesions involving the clitoris, urethra, or perineal body, multi-disciplinary input from gynaecological oncology, urology, and plastic surgery ensures an oncologically safe and anatomically appropriate resection.

4. Sentinel Lymph Node Biopsy (SLNB)

For early-stage invasive vulval SCC (T1b/T2, no suspicious nodes on imaging), SLNB has replaced complete inguinofemoral lymphadenectomy as the standard nodal staging procedure. A radioactive tracer and/or blue dye is injected peri-tumorally to identify the first-draining (sentinel) node(s) in the groins. Excision of sentinel nodes only dramatically reduces the morbidity of inguinal lymphadenectomy (particularly lymphoedema) while maintaining equivalent accuracy for nodal metastasis detection.

5. Laser and Electrosurgical Ablation

For extensive, multifocal VIN without suspicion of invasion, CO2 laser ablation or electrosurgical loop excision (LEEP/LLETZ) can treat large areas of abnormal epithelium with less scarring and better cosmetic outcome than wide excision. The trade-off is the absence of a histological specimen to confirm excision depth and rule out occult invasion — making a preceding biopsy essential.

6. Plastic Surgical Reconstruction

Large vulval defects following radical excision may require reconstructive procedures to achieve primary closure, reduce post-operative contracture, and optimize functional and cosmetic outcomes. Techniques include rhomboid flaps, lotus petal flaps, gracilis myocutaneous flaps, and gluteal thigh flaps, performed by plastic or gynaecological oncology surgeons with reconstructive expertise.

Vulval lesion excision provides multiple diagnostic, therapeutic, and preventive benefits:

Diagnostic Value

All excised tissue undergoes formal histopathological assessment, providing definitive diagnosis, VIN grading, confirmation of invasive vs. in-situ disease, and assessment of surgical margins. This information is essential for determining whether further treatment is needed and for risk stratification during follow-up. Punch biopsy alone may miss focal areas of invasion within a larger VIN lesion — excision provides the complete specimen.

Therapeutic Benefits

• Symptom relief: Pruritus, burning, pain, bleeding, and discomfort from vulval lesions resolve promptly after excision. Relief of chronic vulval symptoms significantly improves quality of life and sexual function.
• Prevention of malignant progression: Excision of VIN eliminates the risk of progression to invasive SCC in the treated area. This is particularly important for dVIN, which carries a 10–33% progression risk compared to 5–10% for uVIN.
• Curative intent for early cancer: Wide local excision with clear margins achieves cure in the majority of women with Stage IA and IB vulval SCC, with 5-year survival rates of 85–90%.
• Pathological staging: Excision of primary vulval cancer with SLNB provides accurate FIGO staging, informing decisions about adjuvant radiotherapy or chemotherapy.

Modern Approach Advantages

Contemporary individualized excision approaches (vs. historical radical vulvectomy) preserve the clitoris, urethral function, perianal tissues, and cosmetic appearance in the majority of patients with VIN and early cancer, dramatically reducing the long-term psychosexual impact of vulval surgery.

The risks of vulval lesion excision vary with the extent of surgery:

Immediate Post-operative Complications

• Wound breakdown/dehiscence: The vulva is a highly vascularized, moist area under chronic friction and bacterial colonization, making primary wound healing challenging. Wound breakdown rates of 20–40% are reported even in the best series, particularly for larger excisions. Most minor breakdowns heal by secondary intention without further surgery, but this can be distressing and prolongs recovery.
• Infection and cellulitis: Surgical site infection is common (10–20%) in the perineal environment. Perioperative antibiotics and careful post-operative wound hygiene reduce but do not eliminate this risk. Signs include increasing pain, redness, swelling, purulent discharge, and fever.
• Haematoma: Blood collection in the surgical dead space, occurring in 3–8% of cases. Small haematomas resolve spontaneously; larger haematomas may require surgical evacuation.

Medium-term Complications

• Scarring and introital stenosis: Excision near the vaginal introitus can lead to scar contracture and narrowing of the vaginal opening, causing dyspareunia (painful intercourse) and difficulties with vaginal examination. Reconstructive techniques and post-operative vaginal dilator use minimize but do not eliminate this risk.
• Lymphoedema: A significant complication when inguinofemoral lymphadenectomy (rather than sentinel node biopsy) is performed. Chronic lower limb lymphoedema develops in 30–70% of patients after complete groin dissection, requiring lifelong compression garments and specialist lymphoedema management. SLNB reduces this rate to <5%.
• Altered sensation and psychosexual effects: Excision near the clitoris, clitoral hood, or urethral meatus may alter sexual sensation. Open discussion before surgery, referral to psychosexual counselling, and physiotherapy (pelvic floor) support are important components of care.

Oncological Risks

• Incomplete excision (positive margins): Positive histological margins increase the risk of local recurrence. Re-excision is recommended when margins are involved and is achievable without significant functional compromise.
• Local recurrence: VIN and vulval cancer can recur after excision, particularly in the context of ongoing HPV infection, lichen sclerosus, or extensive/multifocal disease. Lifelong surveillance is mandatory.

Recovery and surveillance after vulval lesion excision are structured to optimize wound healing, assess oncological outcomes, and detect recurrence early:

Immediate Recovery (Days 1–14)

• Patients are advised on perineal hygiene: regular salt-water baths (sitz baths), gentle cleansing after micturition and defecation, and keeping the wound dry and aerated where possible.
• A urethral catheter may be placed for 24–48 hours in cases where excision is adjacent to the urethra or where a large wound closure limits comfortable voiding.
• Pain is managed with regular paracetamol, NSAIDs (if tolerated), and short-course opioids if needed for larger excisions.
• Patients are encouraged to mobilize early but avoid prolonged sitting or strenuous activity for 2–4 weeks.
• Wound checks are scheduled at 1–2 weeks to assess healing; minor wound breakdown is managed with wound care instructions and district nursing support if required.

Medium-term Recovery (Weeks 2–8)

• Most women can return to light work within 2–3 weeks for minor excisions, and 4–6 weeks after larger procedures.
• Sexual intercourse is typically deferred for 6–8 weeks until wound healing is confirmed.
• Physiotherapy referral for pelvic floor exercises is offered, particularly after procedures involving the perineal body.
• Psychosexual counselling is offered to all patients as part of holistic care.

Oncological Surveillance

• VIN: Review with colposcopy at 6 months and 12 months post-excision, then annually for life. HPV vaccination (even in older women with HPV-related VIN) reduces recurrence rates and should be offered.
• Vulval cancer: 3-monthly follow-up for the first 2 years (the highest risk period for recurrence), then 6-monthly for years 3–5, then annually. Vulval examination and groin palpation are performed at each visit; imaging is requested if recurrence is suspected.

The cost of vulval lesion excision varies considerably by indication, extent of surgery, and healthcare system:

Cost Components

• Gynaecological oncology or gynaecology surgeon fees
• Anaesthesiology fees (local, spinal, or general)
• Hospital facility, operating room, and recovery charges
• Histopathology and molecular testing (HPV testing, p53 staining for dVIN)
• Sentinel lymph node mapping (radiotracer, gamma probe): additional USD 500–1,500
• Reconstructive surgery costs (if flap reconstruction required)
• Post-operative physiotherapy, wound care nursing, psychosexual counselling
• Follow-up colposcopy and surveillance visits

Estimated Costs by Region

• United States: USD 5,000–20,000 for wide local excision (surgeon + facility + anesthesia + histology); USD 20,000–60,000 for radical excision with lymphadenectomy. Covered by most insurance for confirmed VIN or malignancy with prior biopsy documentation.
• United Kingdom: Fully covered under NHS for medical indications. Private sector: GBP 3,000–15,000 depending on extent.
• India: USD 1,500–6,000 at accredited tertiary gynaecological oncology centres. Leading centres in New Delhi, Mumbai (Tata Memorial Hospital), and Bengaluru offer world-class gynaecological oncology surgery at significantly lower cost than Western centres.
• Thailand: USD 3,000–8,000; internationally accredited hospitals in Bangkok (Bumrungrad, Samitivej)
• Malaysia: USD 2,500–7,000; University Malaya Medical Centre and private hospitals in Kuala Lumpur
• Turkey: USD 2,000–6,000; internationally trained gynaecological oncologists in Istanbul and Ankara

Insurance Considerations

Excision of VIN, Paget's disease, and vulval cancer is covered by most health insurance schemes when preceded by a histologically confirmed pre-operative biopsy. Excision of benign symptomatic lesions (Bartholin cysts, large condylomata) is generally also covered. Cosmetic or elective procedures without a medical indication may not be covered and require pre-authorization.

For selected patients, non-surgical or minimally invasive options exist as alternatives or adjuncts to formal surgical excision:

Topical Imiquimod (Aldara)

A topical immune response modifier applied 3 times weekly for 12–20 weeks. Imiquimod stimulates local immune surveillance (via toll-like receptor 7 activation) to clear HPV-infected cells. Multiple randomised controlled trials show complete regression rates of 30–50% for usual-type (HPV-associated) VIN, with a further 30–40% achieving partial regression. Imiquimod is a first-line option for women with multifocal uVIN where excision would be extensive. Limitations include local skin reactions (soreness, erythema, ulceration), variable response, need for pathological confirmation of lesion type before initiation, and inability to provide a histological specimen. It is not effective for dVIN (which is HPV-independent).

Laser Ablation

CO2 laser vaporization destroys abnormal epithelium with precision and minimal thermal damage to surrounding structures. It is particularly valuable for extensive uVIN involving the clitoral hood or interlabial sulci where excision would be functionally damaging. Healing is excellent, with good cosmetic and functional outcomes. As with all ablative techniques, an invasive cancer must be excluded by prior biopsy before laser ablation. Recurrence rates are broadly similar to excision for uVIN.

Photodynamic Therapy (PDT)

5-aminolaevulinic acid (5-ALA) is applied to the vulval lesion, then the area is exposed to specific-wavelength light, selectively destroying HPV-infected cells. PDT is available at specialist centres and is suitable for superficial, HPV-related disease. Responses are similar to imiquimod, with the advantage of shorter treatment duration.

Observation (Small Lesions, Low-risk VIN)

Very small, stable, asymptomatic VIN lesions in young women — particularly confirmed as low-grade uVIN after thorough colposcopy and biopsy — may be kept under surveillance with 6-monthly colposcopy rather than immediate treatment. Some lesions regress spontaneously, particularly in pregnant women. This approach requires excellent patient compliance and clear documentation of follow-up plans.

Radiotherapy

Primary radiotherapy (with or without concurrent sensitizing chemotherapy) is used for invasive vulval cancers that are not amenable to primary surgical excision due to proximity to the urethra, clitoris, or anus where surgical resection would result in incontinence. Chemoradiation also plays a role in the adjuvant setting after surgery for node-positive or margin-positive disease.